IR@PKUHSC  > 基础医学院  > 病理学系
学科主题基础医学
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing
Liu, Yan1; Wu, Bing-Quan1; Zhong, Hao-Hao1; Hui, Pei2; Fang, Wei-Gang1
关键词EGFR KRAS FFPE hydrothermal pressure lung cancer mutation analysis
刊名INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
2013
6期:9页:1880-1889
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Pathology
研究领域[WOS]Oncology ; Pathology
关键词[WOS]GROWTH-FACTOR-RECEPTOR ; TYROSINE KINASE INHIBITORS ; TRANSBRONCHIAL NEEDLE ASPIRATION ; CANCER ; BIOPSY ; ADENOCARCINOMAS ; RESISTANCE ; GEFITINIB ; FREQUENT ; SAMPLES
英文摘要

EGFR and KRAS mutations correlate with response to tyrosine kinase inhibitors in patients with non-small cell lung carcinoma (NSCLC). We reported a hydrothermal pressure method of simultaneous deparaffinization and lysis of formalin-fixed paraffin embedded (FFPE) tissue followed by conventional chaotropic salt column purification to obtain high quality DNA for mutation analysis using PCR-base direct sequencing. This study assessed the feasibility of using this method to screen for exons 18-21 of EGFR and exon 2 of KRAS gene mutations in surgical resection and core needle biopsy specimens from 251 NSCLC patients. EGFR mutations were identified in 140 (55.8%) NSCLC patients (118 in adenocarcinoma, 11 in squamous cell carcinoma, 7 in adenocarcinoma and 4 in NSCLC-not otherwise specified), including four novel substitutions (L718M, A743V, L815P, V819E). EGFR mutations were frequently present in female patients (72 of 113, 63.7%) and NSCLC with adenocarcinoma component (125/204, 61.3%) with statistical significance. Twenty-one patients had multiple mutations at different exons of EGFR, in which seventeen patients had deletions in exon 19. KRAS mutations were found in 18 (7.2%) patients (15 in adenocarcinoma, 2 in squamous cell carcinoma and one in NSCLC-not otherwise specified), including an uncommon substitution G13C. Deparaffinization and lysis by hydrothermal pressure, coupled with purification and PCR-based sequencing, provides a robust screening approach for EGFR and KRAS mutation analysis of FFPE tissues from either surgical resection or core needle biopsy in clinical personalized management of lung cancer.

语种英语
WOS记录号WOS:000324316600020
引用统计
被引频次:19[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
版本出版稿
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55634
专题基础医学院_病理学系
作者单位1.Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China
2.Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
推荐引用方式
GB/T 7714
Liu, Yan,Wu, Bing-Quan,Zhong, Hao-Hao,et al. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing[J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY,2013,6(9):1880-1889.
APA Liu, Yan,Wu, Bing-Quan,Zhong, Hao-Hao,Hui, Pei,&Fang, Wei-Gang.(2013).Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY,6(9),1880-1889.
MLA Liu, Yan,et al."Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing".INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 6.9(2013):1880-1889.
条目包含的文件 下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Screening for EGFR a(444KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 下载
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Yan]的文章
[Wu, Bing-Quan]的文章
[Zhong, Hao-Hao]的文章
百度学术
百度学术中相似的文章
[Liu, Yan]的文章
[Wu, Bing-Quan]的文章
[Zhong, Hao-Hao]的文章
必应学术
必应学术中相似的文章
[Liu, Yan]的文章
[Wu, Bing-Quan]的文章
[Zhong, Hao-Hao]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。